Open Label Optimization Study

Active, not recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

October 15, 2026

Study Completion Date

April 15, 2027

Conditions
Major Depressive Disorder
Interventions
DEVICE

SAINT® Neuromodulation System (NMS)

The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.

Trial Locations (7)

11249

Fermata, Brooklyn

90025

LA TMS, Los Angeles

92626

BrainHealth Solutions, Costa Mesa

94085

Integral TMS, Sunnyvale

94087

Acacial Research Center, Sunnyvale

98104

Seattle Neuropsychiatric Treatment Center, Seattle

01760

Boston Precision Neurotherapeutics, Natick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Magnus Medical

INDUSTRY

NCT05819021 - Open Label Optimization Study | Biotech Hunter | Biotech Hunter